138 related articles for article (PubMed ID: 28625283)
1. Uterine and Ovarian Carcinosarcomas: Do They Behave Similarly?
Ureyen I; Karalok A; Cirik DA; Tasci T; Gokce ZK; Duzguner IB; Tulunay G; Turan T
J Obstet Gynaecol Can; 2017 Jul; 39(7):559-563. PubMed ID: 28625283
[TBL] [Abstract][Full Text] [Related]
2. Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival.
Rojas C; Tian C; Powell MA; Chan JK; Bateman NW; Conrads TP; Rocconi RP; Jones NL; Shriver CD; Hamilton CA; Maxwell GL; Casablanca Y; Darcy KM
Gynecol Oncol; 2020 Apr; 157(1):67-77. PubMed ID: 32029291
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.
Şükür YE; Taşkın S; Varlı B; Ateş C; Güngör M; Ortaç F
Int J Clin Oncol; 2018 Feb; 23(1):114-120. PubMed ID: 28836024
[TBL] [Abstract][Full Text] [Related]
4. Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group.
Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
Gynecol Oncol; 2016 Jun; 141(3):447-453. PubMed ID: 27072806
[TBL] [Abstract][Full Text] [Related]
5. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.
Pacaut C; Bourmaud A; Rivoirard R; Moriceau G; Guy JB; Collard O; Bosacki C; Jacquin JP; Levy A; Chauleur C; Magné N; Merrouche Y
Am J Clin Oncol; 2015 Jun; 38(3):272-7. PubMed ID: 23751320
[TBL] [Abstract][Full Text] [Related]
6. Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas.
Cicin İ; Özatlı T; Türkmen E; Özturk T; Özçelik M; Çabuk D; Gökdurnalı A; Balvan Ö; Yıldız Y; Şeker M; Özdemir N; Yapar B; Tanrıverdi Ö; Günaydin Y; Menekşe S; Öksüzoğlu B; Aksoy A; Erdogan B; Bekir Hacıoglu M; Arpaci E; Sevinç A
Balkan Med J; 2016 Sep; 33(5):517-524. PubMed ID: 27761279
[TBL] [Abstract][Full Text] [Related]
7. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Saito A; Nishikawa T; Yoshida H; Mizoguchi C; Kitadai R; Yamamoto K; Yazaki S; Kojima Y; Ishikawa M; Kato T; Yonemori K
Gynecol Oncol; 2023 Sep; 176():115-121. PubMed ID: 37506533
[TBL] [Abstract][Full Text] [Related]
8. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.
Berton-Rigaud D; Devouassoux-Shisheboran M; Ledermann JA; Leitao MM; Powell MA; Poveda A; Beale P; Glasspool RM; Creutzberg CL; Harter P; Kim JW; Reed NS; Ray-Coquard I
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S55-60. PubMed ID: 25341582
[TBL] [Abstract][Full Text] [Related]
9. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
10. Prognostic determinants in patients with uterine and ovarian carcinosarcoma.
Rauh-Hain JA; Shoni M; Schorge JO; Goodman A; Horowitz NS; del Carmen MG
J Reprod Med; 2013; 58(7-8):297-304. PubMed ID: 23947079
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network.
Romeo C; Le Saux O; Jacobs M; Joly F; Ferron G; Favier L; Fumet JD; Isambert N; Colombo PE; Sabatier R; Bastide L; Charreton A; Devouassoux-Shisheboran M; Gertych W; Dubot C; Bello Roufai D; Bataillon G; Berton D; Kalbacher E; Pautier P; Pomel C; Cornou C; Treilleux I; Lardy-Cleaud A; Ray-Coquard I
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053517
[TBL] [Abstract][Full Text] [Related]
12. Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression.
Kitadai R; Nishikawa T; Yoshida H; Mizoguchi C; Yamamoto K; Kato T; Yonemori K
J Gynecol Oncol; 2024 Mar; 35(2):e11. PubMed ID: 37914528
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08).
Cha J; Kim YS; Park W; Kim HJ; Kim JY; Kim JH; Kim J; Yoon WS; Kim JW; Kim YB
J Gynecol Oncol; 2016 Nov; 27(6):e58. PubMed ID: 27550404
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Adjuvant Pelvic Radiotherapy on Distant Metastasis for Uterine Carcinosarcoma.
Eng NL; Rana SR; Hall KL; Eng TY
Am J Clin Oncol; 2021 Apr; 44(4):169-173. PubMed ID: 33481373
[TBL] [Abstract][Full Text] [Related]
15. Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome.
George EM; Herzog TJ; Neugut AI; Lu YS; Burke WM; Lewin SN; Hershman DL; Wright JD
Gynecol Oncol; 2013 Oct; 131(1):42-5. PubMed ID: 23838036
[TBL] [Abstract][Full Text] [Related]
16. Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis.
Rauh-Hain JA; Gonzalez R; Bregar AJ; Clemmer J; Hernández-Blanquisett A; Clark RM; Schorge JO; Del Carmen MG
Gynecol Oncol; 2016 Jul; 142(1):38-43. PubMed ID: 27107722
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
Matsuo K; Bond VK; Im DD; Rosenshein NB
Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
[TBL] [Abstract][Full Text] [Related]
18. Uterine carcinosarcoma: A review of the literature.
Cantrell LA; Blank SV; Duska LR
Gynecol Oncol; 2015 Jun; 137(3):581-8. PubMed ID: 25805398
[TBL] [Abstract][Full Text] [Related]
19. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
20. Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma.
Signorelli M; Chiappa V; Minig L; Fruscio R; Perego P; Caspani G; Battistello M; Colombo N
Int J Gynecol Cancer; 2009 Aug; 19(6):1142-6. PubMed ID: 19820383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
